These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1419299)

  • 21. Mammographic aspect, cell kinetics and hormone receptor status of operable breast cancer.
    Paradiso A; Ventrella V; Farchi G; Tommasi S; Mangia A; Barletta A; Schittulli F; Racanelli A; De Lena M
    Oncology; 1993; 50(2):104-9. PubMed ID: 8383827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
    Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
    Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Steroid hormone receptors and their relevance for the therapy of mammary cancers (author's transl)].
    Heise E
    Arch Geschwulstforsch; 1981; 51(8):727-36. PubMed ID: 7041847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting survival in bilateral breast carcinoma.
    Alexander AI; Mercer RJ; Muir IM; Mason B; Holdaway I
    Aust N Z J Surg; 1989 Jan; 59(1):35-7. PubMed ID: 2913992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
    Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
    Anticancer Res; 1991; 11(5):1701-6. PubMed ID: 1768039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.
    Stål O; Carstensen J; Hatschek T; Nordenskjöld B
    Br J Cancer; 1992 Oct; 66(4):706-11. PubMed ID: 1419611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen receptor heterogeneity and the relationship between estrogen receptor and the tritiated thymidine labeling index in human breast cancer.
    Straus MJ; Moran R; Muller RE; Wotiz HH
    Oncology; 1982; 39(4):197-200. PubMed ID: 7088469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers.
    Silvestrini R; Daidone MG; Benini E; Faranda A; Tomasic G; Boracchi P; Salvadori B; Veronesi U
    Clin Cancer Res; 1996 Dec; 2(12):2007-13. PubMed ID: 9816160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
    Clarke RB; Laidlaw IJ; Jones LJ; Howell A; Anderson E
    Br J Cancer; 1993 Mar; 67(3):606-11. PubMed ID: 8439511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
    Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
    Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome.
    Mangia A; De Lena M; Barletta A; Marzullo F; Attolico M; Stea B; Petroni S; Labriola A; Cellamare G; Digiesi G; Altieri R; Schittulli F; Paradiso A
    J Exp Clin Cancer Res; 1998 Sep; 17(3):317-23. PubMed ID: 9894769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. int-2 oncogene amplification and prognosis in node-negative breast carcinoma.
    Fioravanti L; Cappelletti V; Coradini D; Miodini P; Borsani G; Daidone MG; Di Fronzo G
    Int J Cancer; 1997 Dec; 74(6):620-4. PubMed ID: 9421359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease.
    Paradiso A; Tommasi S; Brandi M; Marzullo F; Simone G; Lorusso V; Mangia A; De Lena M
    Cancer; 1989 Nov; 64(9):1922-7. PubMed ID: 2790702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors.
    Stierer M; Rosen H; Weber R; Hanak H; Spona J; Tüchler H
    Ann Surg; 1993 Jul; 218(1):13-21. PubMed ID: 8328824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
    Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
    Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
    Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
    Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of presence of progesterone receptors to prognosis in early breast cancer.
    Pichon MF; Pallud C; Brunet M; Milgrom E
    Cancer Res; 1980 Sep; 40(9):3357-60. PubMed ID: 7427948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors. Stage and receptor status in breast cancer.
    Donegan WL
    Cancer; 1992 Sep; 70(6 Suppl):1755-64. PubMed ID: 1516031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.